Showing 2,373 news articles about HIV treatment

Filters Content type: Editors' picks Topic: HIV treatment

Treatment is recommended for all people living with HIV. It involves taking a combination of antiretroviral drugs. This stops the virus from replicating and allows the immune system to strengthen and fight infections.

Changing treatment

ZAMBIA: Ephraim Banda, The third-line drugs we don't have

Editor's pick
IRIN Plus News
23 November 2010
New & experimental HIV treatments

J&J, U.S. sue Mylan and Lupin to block generic copy of HIV drug

Editor's pick
Bloomberg
20 November 2010
Changing treatment

All HIV patients to get second-line treatment free

Editor's pick
Times of India
13 November 2010
Drug interactions & pharmacokinetics

Drug Interaction iPhone app: review

Editor's pick
Positive Pulse
11 November 2010
How HIV works

X-rays illuminate the mechanism used by HIV to attack human DNA

Editor's pick
Imperial College London
11 November 2010
Side effects

FDA Okays First Drug for Lipodystrophy

Editor's pick
MedPage Today HIV/AIDS
11 November 2010
Side effects

Complications reported in some recipients of Bio Alcamid

Editor's pick
CATIE
7 November 2010
New & experimental HIV treatments

Workshop report: “Towards a Cure: HIV Reservoirs and Strategies to Control Them”

Editor's pick
Journal of International AIDS Society
4 November 2010
New & experimental HIV treatments

Crofelemer ADVENT trial demonstrates highly statistically significant results in the treatment of HIV-associated diarrhea

Editor's pick
Market Watch
4 November 2010
Resistance

Uganda: HIV's Deadliest Strain

Editor's pick
AllAfrica
3 November 2010
Hepatitis C treatment

Bristol-Myers, Gilead seek AIDS cocktail success in hepatitis C

Editor's pick
Bloomberg
30 October 2010
New & experimental HIV treatments

How we fix America’s dated drug approval process

Editor's pick
The Hill
28 October 2010
Ageing & HIV

Updates from the 1st International Workshop on HIV & Aging

Editor's pick
The Body
27 October 2010
Generic medicines

Generic erosion of key antiretroviral agents will limit growth in the HIV drug market to 2.2 percent a year from 2014 to 2019

Editor's pick
PR Newswire
27 October 2010
Side effects

IDSA: No Race or Gender Safety Issues Observed in Studies (CME/CE)

Editor's pick
MedPage Today HIV/AIDS
24 October 2010
Adherence

IDSA: Experienced Providers May Boost HIV Treatment Adherence (CME/CE)

Editor's pick
MedPage Today HIV/AIDS
24 October 2010
Starting treatment

IDSA: Physicians Lag in Adopting Earlier Tx Initiation (CME/CE)

Editor's pick
MedPage Today HIV/AIDS
23 October 2010
Adherence

IDSA: Cell Phones Improve HIV Care (CME/CE)

Editor's pick
MedPage Today HIV/AIDS
23 October 2010
New & experimental HIV treatments

IDSA: Cancer Gene Plays Key Role in HIV Infection (CME/CE)

Editor's pick
MedPage Today HIV/AIDS
22 October 2010
Neurological & cognitive problems

Neurotune presents positive dimiracetam Phase IIa results for treatment of neuropathic pain in HIV-positive patients

Editor's pick
Pharmaceutical Business Review
22 October 2010
New & experimental HIV treatments

Shionogi-ViiV Healthcare begin two phase III studies for investigational once-daily HIV integrase inhibitor

Editor's pick
Market Watch
21 October 2010
Starting treatment

Gilead Profit Beats Forecasts on Jump in HIV Drug Sales

Editor's pick
CNBC
19 October 2010
New & experimental HIV treatments

Cytheris Announces Initiation of ORVACS-Sponsored Phase II Clinical Study to Attack Viral Reservoir of HIV Patients

Editor's pick
Reuters
19 October 2010
Neurological & cognitive problems

NeurogesX to pursue expanded U.S. label for Qutenza® (capsaicin) 8% patch in HIV-associated neuropathy

Editor's pick
PR Newswire
18 October 2010